FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileValeo Pharma Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VPHIF
Valeo Pharma Inc. Stock AnalysisComprehensive stock analysis for Valeo Pharma Inc. (VPHIF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVPHIF
VPHIF
Valeo Pharma Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VPHIF
Home🔹Stocks🔹Valeo Pharma Inc.

Valeo Pharma Inc.

🇺🇸VPHIF•OTC

Valeo Pharma Inc.

🇺🇸VPHIF•OTC
Market cap
$9.87K
Sentiment

Your view on VPHIF

Mkt Cap
$9.87K
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Valeo Pharma Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kyle Steiger
Headquarters
16667 Hymus Boulevard, Kirkland, QC, CA
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Kyle Steiger
Headquarters
16667 Hymus Boulevard, Kirkland, QC, CA
Description

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada.

Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.

In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic.

The company was incorporated in 2003 and is headquartered in Kirkland, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

Fair value for Valeo Pharma Inc. from FRC's valuation model, read against the market price. VPHIF last traded at $0.0001; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Valeo Pharma Inc.. Starting points for Valeo Pharma Inc.: EPS -$0.32, beta 0.71 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Valeo Pharma Inc.. Valeo Pharma Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Valeo Pharma Inc.. Trailing twelve-month EPS for Valeo Pharma Inc. stands at -$0.32. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

As of Nov 13, 2026 · CAD

Earnings Estimate

EPSCurrent QtrOct 2024Next QtrJan 2026Current YearFY Oct 2024Next YearFY Oct 2025
Avg. estimate-CAD 0.03-CAD 0.03-CAD 0.27-CAD 0.14
Low estimate-CAD 0.03-CAD 0.03-CAD 0.27-CAD 0.14
High estimate-CAD 0.03-CAD 0.03-CAD 0.27-CAD 0.14
No. of analysts1111
Year-ago EPS-CAD 0.10-CAD 0.08-CAD 0.32—
Growth+69.5%+58.9%+15.7%—

Revenue Estimate

RevenueCurrent QtrOct 2024Next QtrJan 2026Current YearFY Oct 2024Next YearFY Oct 2025
Avg. estimateCAD 15.98MCAD 5.22MCAD 58.02MCAD 69.69M
Low estimateCAD 15.98MCAD 5.22MCAD 58.02MCAD 69.69M
High estimateCAD 15.98MCAD 5.22MCAD 58.02MCAD 69.69M
No. of analysts1111
Year-ago revenueCAD 13.11MCAD 13.54MCAD 53.91M—
Growth+21.9%-61.4%+7.6%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Valeo Pharma Inc.. Valeo Pharma Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Valeo Pharma Inc. valued side by side against its closest peers. Valeo Pharma Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

News

Latest headlines and market coverage.

Latest headlines and company announcements for Valeo Pharma Inc.. Coverage tracks Valeo Pharma Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Valeo Pharma Inc.

Peer companies

  • ALRTFALR Technologies Inc.
  • CHHEChina Health Industries Holdings, Inc.
  • ECGSEco-Growth Strategies Inc.
  • IMUCEOM Pharmaceuticals Holdings, Inc.
  • LUFFFHerbal Dispatch Inc.
  • LVCLFAlgorae Pharmaceuticals Limited

More Drug Manufacturers - Specialty & Generic companies

  • LITHBioELife Corp.
  • LMLLFPharmadrug Inc.
  • LNTHLantheus Holdings, Inc.
  • LOVE.TOCannara Biotech Inc.
  • LOVFFCannara Biotech Inc.
  • LOWLFLowell Farms Inc.
  • LTHOLegacy Technology Holdings, Inc.
  • LVRLFCordovaCann Corp.
  • LVVVLiveWire Ergogenics, Inc.
  • LVZPFLivzon Pharmaceutical Group Inc.
  • LYPHFLuye Pharma Group Ltd.
VPHIF Analysis
Weak
Past1
Growth5
Health1
Profit1
Value1

News

Latest Market News